Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Ltd.

www.cipla.com

Latest From Cipla Ltd.

Reality Check? Granules Moves Out Of China JV

Indian firm Granules is exiting its long-standing joint venture for ibuprofen API in China against the backdrop of evolving pollution control norms and the need for growing expenditure there, while emerging supply options have reduced the need for a local JV.

Commercial Strategy

The Factory Floor: Suanfarma Expands API Capacity With Sandoz Deal In Italy

Suanfarma acquires an API manufacturing facility in Italy to accelerate its growth in Europe, while CapsCanada relocates its headquarters as part of its growth strategy. Meanwhile, Glenmark, Aurobindo and Cipla struggle with quality issues.

Manufacturing Regulation

Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy

Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.

Research & Development India

Eisai-Mylan Tango for Second Halaven Brand In India But Eyes On Pricing, Generics

Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.

India Commercial
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Dermatology
  • Gynecological, Urological
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Cipla Ltd.
  • Senior Management
  • Umang Vohra, Managing Dir. & Global CEO
    Kedar Upadhye, Global CFO
  • Contact Info
  • Cipla Ltd.
    Phone: (91) 22 24826000
    Peninsula Business Park
    Lower Parel
    Mumbai, 400008
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register